{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:35:12Z","timestamp":1781951712905,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Global Napi Pharmaceuticals for Global Advanced Pharmaceuticals, Egypt."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40268-025-00526-5","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:46:40Z","timestamp":1763434000000},"page":"343-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study"],"prefix":"10.1007","volume":"25","clinical-trial-number":[{"clinical-trial-number":"nct06969963","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1690","authenticated-orcid":false,"given":"Aya M.","family":"AbdelMagid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal A.","family":"Badr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-4390","authenticated-orcid":false,"given":"Mamdouh R.","family":"Rezk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"526_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.seizure.2022.09.020","volume":"102","author":"A Lavu","year":"2022","unstructured":"Lavu A, Aboulatta L, Abou-Setta AM, Aloud B, Askin N, Rabbani R, et al. Efficacy and safety of perampanel in epilepsy: a systematic review and meta-analysis of randomised controlled trials. Seizure. 2022;102:54\u201360.","journal-title":"Seizure"},{"key":"526_CR2","unstructured":"World Health Organization (WHO). Epilepsy. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy\/?gad_source=1&gclid=EAIaIQobChMI_6ihu8SsigMVpG9BAh3TrQHlEAAYASAAEgISEfD_BwE. Accessed 16 Dec 2024."},{"issue":"7","key":"526_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","volume":"52","author":"T Hanada","year":"2011","unstructured":"Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331\u201340. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03109.x.","journal-title":"Epilepsia"},{"issue":"11","key":"526_CR4","first-page":"683","volume":"41","author":"J Greenwood","year":"2016","unstructured":"Greenwood J, Valdes J. Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016;41(11):683\u201398.","journal-title":"P T"},{"issue":"3","key":"526_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40261-022-01241-8","volume":"43","author":"S Jing","year":"2023","unstructured":"Jing S, Shiba S, Morita M, Yasuda S, Lin Y. A single- and multiple-dose pharmacokinetic study of oral perampanel in healthy Chinese subjects. Clin Drug Investig. 2023;43(3):155\u201365.","journal-title":"Clin Drug Investig"},{"key":"526_CR6","unstructured":"European Medicines Agency. Fycompa 0.5 mg-ml oral susp\u2014Summary of Product Characteristics (SmPC) [Internet]. 2020 [cited 2024 Dec 14]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf"},{"issue":"1","key":"526_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12865","volume":"56","author":"PN Patsalos","year":"2015","unstructured":"Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12\u201327.","journal-title":"Epilepsia"},{"key":"526_CR8","unstructured":"FDA Draft Guidance. Bioequivalence studies with pharmacokinetic edndpoints for drugs submitted under an ANDA. FDA Guidance. 2021;(August):24."},{"key":"526_CR9","unstructured":"Robert L, Levin M. Cross_discipline team leader review. Reference ID: 3924252. 2016; https:\/\/www.fda.gov\/files\/drugs\/published\/20-272S065-Risperidone-Clinical-CTDL-PREA.pdf. Accessed 12 Oct 2025."},{"key":"526_CR10","unstructured":"Therapeutic Goods Administration (TGA). ICH guideline for good clinical practice. 2018. https:\/\/www.tga.gov.au\/resources\/publication\/publications\/ich-guideline-good-clinical-practice. Accessed 3 Jan 2025."},{"issue":"20","key":"526_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"526_CR12","unstructured":"US Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug. Accessed 14 Apr 2023."},{"key":"526_CR13","unstructured":"US Food and Drug Administration. Bioanalytical method validation guidance for industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry. Accessed 14 Apr 2023."},{"issue":"1","key":"526_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4155\/bio.13.298","volume":"6","author":"D Zimmer","year":"2014","unstructured":"Zimmer D, New US. FDA draft guidance on bioanalytical method validation versus current FDA and EMA guidelines: chromatographic methods and ISR. Bioanalysis. 2014;6(1):13\u20139.","journal-title":"Bioanalysis"},{"key":"526_CR15","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Clinical Pharmacology and Biopharmaceutics Review (S) Application Number: 208277Orig1s000. 2009. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208277Orig1s000ClinPharmR.pdf. Accessed 12 Oct 2025."},{"key":"526_CR16","unstructured":"Philip H. Sheridan WHD. Perampanel Summary Review. Reference ID: 4327224 [Internet]. 2019 [cited 2024 Dec 14]. p. 1\u201314. https:\/\/www.fda.gov\/media\/124207\/download"},{"issue":"3","key":"526_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","volume":"34","author":"WA Hauser","year":"1993","unstructured":"Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935\u20131984. Epilepsia. 1993;34(3):453\u201368.","journal-title":"Epilepsia"},{"issue":"3\u20134","key":"526_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000493484","volume":"51","author":"E Beghi","year":"2018","unstructured":"Beghi E, Giussani G. Aging and the epidemiology of epilepsy. Neuroepidemiology. 2018;51(3\u20134):216\u201323.","journal-title":"Neuroepidemiology"},{"issue":"12","key":"526_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.5414\/CP203781","volume":"58","author":"S Shiba","year":"2020","unstructured":"Shiba S, Sekino H, Ishiba K, Yasuda S, Inoue S, Kotaka K, et al. Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects. Int J Clin Pharmacol Ther. 2020;58(12):757\u201364.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"526_CR20","unstructured":"Egyptian Drug Authority (EDA). Egyptian Guideline for Conducting Bioequivalence Studies for Marketing Authorization of Generic Products [Internet]. 2023 [cited 2024 Dec 20]. https:\/\/www.edaegypt.gov.eg\/media\/dyihv0tm\/egyptian-guidelines-for-conducting-bioequivalence-studies-for-ma-1.pdf."},{"key":"526_CR21","unstructured":"Egyptian Drug Authority (EDA). 2021. Guidance for conducting bioavailability and bioequivalence studies. https:\/\/edaegypt.gov.eg. Accessed 6 Aug 2025."},{"key":"526_CR22","doi-asserted-by":"crossref","unstructured":"Laurenza A, Hall N, Majid O, Rege B. Bioequivalence evaluation of perampanel oral suspension and tablet formulations in healthy subjects: a phase I, open-label, crossover study (P3.240). Neurology [Internet]. 2017;88(16_supplement):P3.240. https:\/\/www.neurology.org\/doi\/10.1212\/WNL.88.16_supplement.P3.240.","DOI":"10.1212\/WNL.88.16_supplement.P3.240"},{"issue":"6","key":"526_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","volume":"79","author":"JA French","year":"2012","unstructured":"French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589\u201396.","journal-title":"Neurology"},{"issue":"1","key":"526_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","volume":"54","author":"JA French","year":"2013","unstructured":"French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117\u201325. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03638.x.","journal-title":"Epilepsia"},{"issue":"18","key":"526_CR25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","volume":"78","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408\u201315.","journal-title":"Neurology"},{"issue":"11","key":"526_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","volume":"85","author":"JA French","year":"2015","unstructured":"French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015;85(11):950\u20137.","journal-title":"Neurology"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00526-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:36:07Z","timestamp":1767188167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00526-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00526-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aya M. AbdelMagid, Kamal A. Badr, and Mamdouh R. Rezk have no conflicts of interest that are directly relevant to the content of this article. Aya M. AbdelMagid is an Editorial Board member of\n                      Drugs in R&D\n                      . Aya M. AbdelMagid was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Independent Ethics Committee of ARC. The ClinicalTrials.gov registration number is NCT06969963, retrospectively registered on 13 May, 2025. All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional committee, the Guidelines for Good Clinical Practice of the International Conference on Harmonisation, and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Prior to the initiation of study procedures, written informed consent was obtained from all participants. The form was explained to all subjects before signing it so that the nature, purpose, benefits, and potential risks of the study were understood.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors read and approved of the final version of the manuscript. They have made contributions to the conception and design of the study, data analysis, interpretation of the results, drafting the article, revising it critically for important intellectual content, and final approval of the version to be submitted. The authors confirm that no paper mill and artificial intelligence was used.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"This paper is dedicated to the soul of the late Prof. Dr. Emad B. Basalious (1974\u20132024), late Professor of Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Dedication"}}]}}